Inactive Instrument

EyeGene Inc. Share Price Other OTC

EYGN.F

KR7185490000

EyeGene Inc is a Korea-based company primarily engaged in research and development in the medical and pharmaceutical fields. The Company is mainly engaged in the research and development of messenger ribonucleic acid (mRNA)-based vaccines. The Company also develops novel treatments for ophthalmic diseases, including treatments for macular degeneration and diabetic retinopathy, as well as adeno-associated virus (AAV) gene therapy targeting rare retinal diseases. In addition, the Company develops a quadrivalent meningococcal vaccine and recombinant botulinum toxin.

Employees

Sector

Pharmaceuticals

More about the company

All transcripts on over 9000 companies, on the day they post their earnings!

Unlock them now!

Market Cap	8.71TCr 6.16Cr 5.32Cr 4.99Cr 4.55Cr 8.55Cr 589.1Cr 8.66Cr 58Cr 23Cr 295.14Cr 23Cr 23Cr 981.76Cr	P/E 2024	-5.71x	P/E 2025	-3.1x
Enterprise Value	4.22TCr 2.98Cr 2.58Cr 2.42Cr 2.2Cr 4.14Cr 285.2Cr 4.19Cr 28Cr 11Cr 142.89Cr 11Cr 11Cr 475.3Cr	EV / Sales 2024	11.6x	EV / Sales 2025	8.48x
Free-Float	70.86%	Yield 2024 *	-	Yield 2025	-

16/25/16	Eyegene Inc to conduct capital increase of 32 billion won for operational funds	RE
21/23/21	EyeGene Inc. announced that it has received KRW 15.000001688 billion in funding from BMI Korea Co., Ltd.	CI
13/23/13	EyeGene Inc. announced that it expects to receive KRW 15.000001688 billion in funding from BMI Korea Co., Ltd.	CI
15/23/15	EyeGene Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI
15/23/15	EyeGene Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	CI
07/22/07	EyeGene Inc.(KOSDAQ:A185490) dropped from S&P Global BMI Index	CI
04/21/04	Maravai LifeSciences : Says Unit TriLink To Supply Proprietary Technology to EyeGene for Production of COVID-19 Vaccine	MT
20/21/20	EyeGene Inc.(KOSDAQ:A185490) added to S&P Global BMI Index	CI
18/20/18	EyeGene Inc. announced that it has received KRW 22 billion in funding from a group of investors	CI
16/20/16	EyeGene Inc. announced that it expects to receive KRW 22 billion in funding from a group of investors	CI
23/19/23	EyeGene Inc.(KOSDAQ:A185490) dropped from S&P Global BMI Index	CI
28/18/28	EyeGene Inc. announced that it has received KRW 29.9998664 billion in funding from Meritz Securities Co., Ltd., Investment Arm, IBK Capital Corporation, Korea Investment & Securities Co., Ltd., Investment Arm	CI
20/18/20	EyeGene Inc. announced that it expects to receive KRW 29.9998664 billion in funding from a group of investors	CI

Manager	Title	Age	Since
Suk-Keun Choi CEO	Chief Executive Officer	59	20/02/2024
Myeong-Jae Lee DFI	Director of Finance/CFO	56	01/05/2012
Won-Il Yoo PSD	President	63	23/06/2000

Director	Title	Age	Since
Won-Il Yoo BRD	Director/Board Member	63	23/06/2000
Myeong-Jae Lee BRD	Director/Board Member	56	20/02/2024
Dal-Hyun Kim BRD	Director/Board Member	64	13/05/2022

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
EYEGENE INC.	-.--%	-.--%	-	-	6.16Cr
ELI LILLY AND COMPANY	+0.25%	-3.96%	+68.73%	+120.06%	1,05500Cr
JOHNSON & JOHNSON	+0.78%	+0.21%	+48.53%	+50.78%	63TCr
ABBVIE INC.	+0.35%	+0.95%	+21.11%	+66.86%	44TCr
ROCHE HOLDING AG	+0.49%	-2.98%	+39.80%	+40.33%	35TCr
NOVARTIS AG	+0.32%	-1.62%	+23.55%	+38.52%	29TCr
ASTRAZENECA PLC	+0.48%	-1.93%	-1.04%	+8.99%	24TCr
AMGEN INC.	+1.00%	+0.52%	+41.46%	+58.95%	23TCr
NOVO NORDISK A/S	-0.47%	-5.09%	-16.10%	-53.40%	20TCr
GILEAD SCIENCES, INC.	+0.40%	+4.40%	+17.36%	+81.59%	17TCr
Average	+0.29%	-1.44%	+27.05%	+45.85%	40.14TCr
Weighted average by Cap.	+0.26%	-1.87%	+39.37%	+64.37%

EyeGene Inc. Share Price Other OTC

Stocks

EYGN.F

KR7185490000

Pharmaceuticals

Valuation: EyeGene Inc.

Latest news : EyeGene Inc.

Managers and Directors: EyeGene Inc.

Other Pharmaceuticals

Financials

Company Profile

	2024	2025
Net sales	335.58Cr 23.74L 20.49L 19.22L 17.51L 32.92L 23Cr 33.38L 2.25Cr 88.31L 11Cr 89.11L 87.18L 38Cr	356.68Cr 25.23L 21.78L 20.43L 18.61L 34.99L 24Cr 35.48L 2.4Cr 93.86L 12Cr 94.72L 92.67L 40Cr
Net income	-1.21TCr -85.78L -74.06L -69.48L -63.28L -1.19Cr -82Cr -1.21Cr -8.14Cr -3.19Cr -41Cr -3.22Cr -3.15Cr -136.69Cr	-1.57TCr -1.11Cr -95.91L -89.97L -81.95L -1.54Cr -106.22Cr -1.56Cr -11Cr -4.13Cr -53Cr -4.17Cr -4.08Cr -177.02Cr
Net Debt	-3.01TCr -2.13Cr -1.84Cr -1.72Cr -1.57Cr -2.95Cr -203.61Cr -2.99Cr -20Cr -7.92Cr -102.01Cr -7.99Cr -7.82Cr -339.32Cr	-4.49TCr -3.18Cr -2.74Cr -2.57Cr -2.34Cr -4.41Cr -303.9Cr -4.47Cr -30Cr -12Cr -152.25Cr -12Cr -12Cr -506.46Cr